Download notification No. S.O. 5939(E) dt 19-12-2022, the link is given below: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 12 scheduled formulations:

Download notification No. S.O. 5939(E) dt 19-12-2022

This price fixation followed the decision of the 105th Authority meeting on December 15, 2022.

In the exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and18 of the Drugs (Prices Control) Order, 2013 (hereinafter to referred as DPCO 2013), read with S.O. 1394(E) dated 30th May 2013 and S.O. 5249(E) dated 11th November 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO 1499(E) dated 30th March, 2022 and SO No 4589(E) dated 29th September, 2022 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the NPPA hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof.

Table

Sl. No.Name of the Scheduled FormulationDosage form and strength  UnitCeiling Price (Rs.)(1)(2)(3)(4)(5)1.AtorvastatinTablet 80mg1 Tablet36.192.CefuroximeOral liquid 125mg/5mL(p)1 ML4.713.LamivudineTablet 100mg1 Tablet9.284.LamivudineTablet 150mg1 Tablet9.695.ItraconazoleOral liquid 10mg/mL1 ML4.416.ValganciclovirTablet 450 mg1 Tablet357.397.LenalidomideCapsule 5mg1 Capsule59.988.MontelukastTablet 4 mg1 Tablet8.959.  MontelukastTablet 5 mg (including chewable Tablet s)  1 Tablet  10.4510.MontelukastTablet 10 mg1 Tablet14.6611.DaclatasvirTablet 60mg1 Tablet178.3412.DolutegravirTablet 50mg1 Tablet100.59

Click for more articles on NPPA

Note:(a) All manufacturers of scheduled formulation, selling the branded or generic or both theversions of scheduled formulations at a price higher than the ceiling price (plus Goods andServices Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRPlower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if itis payable to the Government on the ceiling price mentioned in column (5) of the above-said table.

Click for more articles on DPCO 2013

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO 2013. The manufacturer shall issue a price list in Form–V from the date of the Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous partof the premises where he carries on business in a manner to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or bothas specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly returns to the NPPA, in respect of the production/import and sale of scheduled formulations in Form-IIIof Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

NPPA updated price lists: Download

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

NPPA revises Retail Price of 107 scheduled formulations: December 2022

NPPA fixes Retail Price of one formulation: November 2022

NPPA fixes Retail Price of 40 formulations: November 2022

NPPA fixes price of 272 new drugs in the first six months of 2022-23

NPPA fixes Retail Prices of 40 Formulations: September 2022

NPPA fixes Retail Prices of 36 Formulations: September 2022

NPPA revises Retail Price of 107 scheduled formulations: December 2022

NABL asks Testing Laboratories to get product based accreditation

Goa FDA allows manufacture and marketing of Ulipristal Acetate Tablets 5mg

Drug Regulators sought Pharmacovigilance (PV) for Gabapentin and Pregabalin

Gujarat FDCA recovers more than Rs. 80 crore in DPCO violations

DCOIWA: Workshop on Medical Device Regulation and Legal Documentation organized

India may become Research Hub in Pharma Sector

DCGI approves this Pneumococcal Conjugate Vaccine

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/21/nppa-fixes-retail-price-of-12-scheduled-formulations-december-2022/